Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Novira Therapeutics

Request full access

Antiviral drug discovery for HBV and HIV

Buckingham Township, United StatesFounded 2009Biotech & Life Sciences

About Novira Therapeutics

Novira Therapeutics was an antiviral drug discovery company focused on creating first-in-class therapeutics for Hepatitis B (HBV) and HIV. The company was co-founded in 2009 by Dr. Ali H. Munawar and Dr. Osvaldo Flores, who served as President and Chief Scientific Officer. Dr. Munawar holds a PhD in X-ray crystallography and structure-based drug design, and was instrumental in the company's research operations. Dr. Flores previously directed antiviral research at Merck.

The company's primary business was the development of small-molecule, oral drugs that inhibit the viral capsid protein, a novel target involved in multiple stages of viral replication and persistence. This mechanism, focused on disrupting capsid assembly, offered a new approach to combatting these viruses, particularly for HBV which lacks a true cure and HIV which can develop drug resistance. Novira's lead candidate was NVR 3-778, a capsid assembly modulator for treating chronic HBV. By targeting the virus core, these drugs aimed to suppress virus production and replication efficiently.

The company operated on a cost-efficient model to reduce the time and expense of delivering drug candidates with clinical proof of concept. In August 2012, Novira secured $23 million in a Series A financing round to advance its pipeline. In November 2015, Johnson & Johnson announced a definitive agreement to acquire Novira Therapeutics, a transaction that was completed in December 2015. Following the acquisition, Novira became part of the Infectious Diseases & Vaccines Therapeutic Area of the Janssen Pharmaceutical Companies of Johnson & Johnson, which continued the development of NVR 3-778.

Source: Dealroom company data

Novira Therapeutics in the Buckingham Township ecosystem

Live from Dealroom

The Novira Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • BioAdvance
  • Robin Hood Ventures
  • Delaware Crossing Investor Group

Series A4 investors entered at this stage

Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Buckingham Township HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Novira Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Novira Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.